Focalin XR (dexmethylphenidate HCl) 5 mg recall — Sandoz Inc (Class III)

Sandoz Inc is recorded by the U.S. Food and Drug Administration (FDA) as recalling Focalin XR (dexmethylphenidate HCl) 5 mg — a Class III recall, initiated 2026-06-01 and posted to the FDA enforcement report on 2026-06-24, under recall number D-0608-2026. Status Ongoing, with no termination date on the record. The reason the FDA record carries is, verbatim: “Labeling: Incorrect or Missing Lot and/or Exp Date”. From the product description, the form is extended-release capsules, the strength given is 5 mg and it is marked Rx only. 1 National Drug Code number is printed in the record: 66758-235-31. Distribution is recorded as “U.S. Nationwide” — Nationwide (US), with the recalling firm on record in NJ, United States. It is the only recall number the FDA has filed under event ID 99121. Values are reproduced from the linked openFDA report; regulatory information, not medical advice.

Regulatory snapshot

Recall number D-0608-2026
FDA event ID 99121
Classification Class III (least serious regulatory tier)
Status Ongoing
Recalling firm Sandoz Inc
Recall initiated 2026-06-01
Reported by FDA 2026-06-24
Report lag 23 days from initiation to report
Distribution U.S. Nationwide — Nationwide (US)
Firm location on record NJ, United States
Product description (source) Focalin XR (dexmethylphenidate HCl) 5 mg, 30 extended-release capsules per bottle, Rx only, Manufactured by Societal CDMO Gainesville, LLC, Gainesville, GA 30504. NDC: 66758-235-31

Reason reported by FDA

Labeling: Incorrect or Missing Lot and/or Exp Date

8 words from the enforcement report field reason_for_recall, reproduced without edit — the firm's own wording, not an assessment.

Product identifiers in this record

4 identifying values matched by exact pattern in the 24-word product description above; each is a literal substring of it.

Product named Focalin XR (dexmethylphenidate HCl) 5 mg
Form Extended-Release Capsules
Strength 5 mg
NDC 66758-235-31
Marketing category Rx only

Reported in the same month (2026-06)

74 enforcement reports carry a report date in 2026-06; these 5 are the Class III ones nearest this record.

Recall recordRecall numberRecalling firmFDA tierReported
Epinephrine Injection, 1mg/mLD-0581-2026Fresenius Kabi Usa, LLCClass III2026-06-17
Primidone Tablets, 50 mgD-0585-2026Amneal Pharmaceuticals, LLCClass III2026-06-17
Lidocaine HCl Injection, 2%D-0552-2026Eugia US LLCClass III2026-06-10
Nicotine Transdermal System Patch, 14 mgD-0550-2026Aveva Drug Delivery Systems, Inc.Class III2026-06-03
PRED MILD, 0.12%D-0551-2026Abbvie Inc.Class III2026-06-03

Nearest Class III recalls by date

25 of 250 indexed records share the Class III tier; the 10 nearest to 2026-06-24 by report date are listed here.

Recall recordRecall numberRecalling firmStrength / formReported
hydrOXYzine Hydrochloride Oral Solution, 10 mg/5 mLD-0619-2026Ani Pharmaceuticals, Inc.10 mg/5 mL · Oral Solution2026-07-01
Fexofenadine Hydrochloride Tablets, 180 mgD-0654-2026Sun Pharmaceutical Industries Inc180 mg · Tablets2026-07-08
Primidone Tablets USP, 250mgD-0533-2026Lannett Company Inc.250mg · Tablets2026-05-27
Primidone Tablets, 50 mgD-0534-2026Golden State Medical Supply Inc.50 mg · Tablets2026-05-27
Primidone Tablets, 250 mgD-0535-2026Golden State Medical Supply Inc.250 mg · Tablets2026-05-27
Primidone Tablets, 250 mgD-0536-2026Amerisource Health Services LLC250 mg · Tablets2026-05-27
Primidone Tablets, 50 mgD-0537-2026Amerisource Health Services LLC50 mg · Tablets2026-05-27
Busulfan Injection, 60 mgD-0539-2026Sagent Pharmaceuticals60 mg · Injection2026-05-27
Lidolog Kit, 2%D-0713-2026Asclemed Usa Inc.2% · Injection2026-07-29
Dabigatran etexilate Capsules, 110 mgD-0735-2026Ascend Laboratories, LLC110 mg · Capsules2026-07-29

Reading this record

Class III is the FDA's own severity tier for the recall action — 25 of the 250 indexed records carry it — and it describes the agency's assessment of the action, not a risk statement about any individual. Match a package against 66758-235-31 at the FDA source to confirm it is covered.

Namespace context: the Class III index (25 records) and the recall hub (250 records, 118 FDA events); Sandoz Inc (4 indexed records) aggregates this firm across datasets.

Coverage and limits of this record

This page reflects the openFDA enforcement report for D-0608-2026 as ingested on 2026-08-22, which can lag the live FDA record and omits detail held only in primary documents. It offers no clinical assessment, no advice about whether to use any product, and no substitute. For any health question consult a qualified healthcare professional.

Source & provenance

Official source
https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0608-2026%22
Source dataset
openFDA Drug Enforcement API
Publication date
2026-06-24
Ingested
2026-08-22
Record hash
a315475c904bca85

Verify every value against the official FDA source above. This site links to the regulator's record rather than replacing it.